Just saw TBPH got hammered 26% after their late-stage ampreloxetine study totally flopped. They were banking on this drug for a rare neurological condition but it didn't hit the primary endpoint. Now they're shutting down the whole R&D division and cutting half their workforce. Pretty brutal. On the flip side, they're doubling down on Yupelri, their LAMA for COPD that's actually selling well. The drug brought in $70.6M in Q4 2025 alone, up 6% year-over-year. For a company that just took a massive L on their pipeline, that LAMA for COPD collaboration with Viatris is looking like their lifeline right now. They're projecting $266.6M in Yupelri sales for full 2025 and expect to cut operating costs by 60% over the next couple quarters. Plus they got $50M from Royalty Pharma on Trelegy, so they're not in immediate trouble cash-wise. Still, watching a biotech pivot this hard from pipeline-focused to basically becoming a commercial drug company is wild. The restructuring should save them like $70M annually by Q3 2026. Curious if this turns into an acquisition target or if they can actually stabilize around the LAMA for COPD franchise. Either way, the stock's getting interesting for value hunters.